Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan

Hseng-Long Yeh, Li-Ying Huang, Syi Su, Ming-Chin Yang and Ting-Chung Wang

Health Policy, 2011, vol. 100, issue 2, 196-202

Abstract: National guidelines recommend angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) therapy for diabetic patients with hypertension and/or proteinuria to hinder renal disease progression. However, little is known about the adequacy of adherence to these guidelines in diabetic patients and about the predictors of such appropriate ACEIs or ARBs use. We sought to define the rates of ACEIs and ARBs use in a large population of patients with diabetic nephropathy (DN).

Keywords: Diabetic nephropathy; Angiotensin-converting enzyme inhibitors; Angiotensin receptor blockers (search for similar items in EconPapers)
Date: 2011
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851010003428
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:100:y:2011:i:2:p:196-202

DOI: 10.1016/j.healthpol.2010.11.010

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().